Antares Pharma Appoints Joseph Renda as Senior Vice President of Commercial
May 06 2021 - 6:15AM
Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty
pharmaceutical company, today announced the appointment of Joseph
V. Renda as Senior Vice President of Commercial. Mr. Renda succeeds
Patrick Shea who resigned to pursue other interests.
Mr. Renda has had a successful career in leading
commercial sales, marketing, and operations at large and mid-sized
pharmaceutical companies. Prior to joining Antares, Mr. Renda was
Vice President, U.S. Sales Autoimmune and Rare Disease at
Mallinckrodt Pharmaceuticals where he led a 200-person organization
responsible for over $1B in annual sales and managed 5 unique
therapeutic areas and institutional account teams. From 2012 to
2018, he held various positions of increasing responsibility at
Novo Nordisk including Marketing Brand Director, Women’s Health
Care and leading the commercial operations and effectiveness
function responsible for a 150-person sales force. He was
ultimately promoted to Vice President, U.S. Sales Biopharmaceutical
Division leading a national sales team with over $600M in annual
sales. Prior to that, he was Regional Business Director at Pfizer
managing one of the largest U.S. sales regions with 175 sales and
account representatives after serving in varying director and
operational roles. He also previously served as Manager, U.S.
Urology Marketing and Alliances at the Pharmacia Corporation and
began his career in sales at The Upjohn Company. Mr. Renda earned
his Bachelor of Science degree from Pennsylvania State
University.
Robert F. Apple, President and Chief Executive
Officer of Antares Pharma, commented, “We are excited to welcome
Joe to Antares. We believe his extensive commercial background
aligns with our strategic initiatives to enhance the strong growth
trajectory of our proprietary portfolio with our flagship product
XYOSTED and our recently launched NOCDURNA. Joe’s proven success in
sales, marketing and sales operations across therapeutic areas will
be instrumental in leading our sales organization and commercial
activities. We expect a seamless transition and remain enthusiastic
about the growth opportunities across our business.”
Mr. Renda, added, “I am honoured with the
opportunity to lead the U.S. commercial team at Antares and build
upon their success to date. I believe their proprietary assets are
well positioned in attractive markets and will continue to capture
market share. I look forward to leveraging my extensive sales,
marketing, and operations experience and contributing to the next
phase of their growth with an expanded portfolio.”
About Antares Pharma
Antares Pharma, Inc. is a specialty
pharmaceutical company focused primarily on the development and
commercialization of pharmaceutical products and technologies that
address unmet needs in targeted therapeutic areas such as urology
and endocrinology. The Company has a portfolio of proprietary and
partnered commercial products with several product candidates in
various stages of development, as well as significant strategic
alliances with industry leading pharmaceutical companies including
Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals
(AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd.
(Idorsia). Antares Pharma’s FDA-approved products include XYOSTED®
(testosterone enanthate) injection, OTREXUP® (methotrexate)
injection for subcutaneous use and Sumatriptan Injection USP, which
is distributed by Teva. The Company also markets NOCDURNA®
(desmopressin acetate) in the U.S., which was licensed from Ferring
Pharmaceuticals.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to: the success of Mr. Renda as SVP,
Commercial and future sales; the Company’s ability to achieve the
2021 full-year revenue guidance; the uncertainty regarding the
ongoing COVID-19 pandemic, including new strains of the virus, and
the mitigation measures and other restrictions implemented in
response to the same and the impact on demand for our products, new
patients and prescriptions, future revenue, product supply,
clinical trials, and our overall business, operating results and
financial condition; commercial success
of XYOSTED® and
future revenue from the same; market acceptance of
Teva’s generic epinephrine auto-injector product and future revenue
from the same; future prescriptions and sales of
OTREXUP® ; successful
commercialization of NOCDURNA® in
the U.S. and market acceptance and future revenue from the
same; whether the FDA will withdraw marketing
approval for AMAG Pharmaceuticals’
Makena® subcutaneous auto
injector following the FDA letter seeking withdrawal, whether AMAG
will be granted an appeal hearing and if granted, whether
Makena® will be successful
and future prescriptions, market acceptance and
revenue from the same; Teva’s ability to successfully commercialize
VIBEX® Sumatriptan Injection USP
and the amount of revenue from the same; Teva’s ability to
successfully commercialize generic teriparatide in Europe, Canada
and Israel and future revenue from the same, successful development
including the timing and results of the Phase 3 clinical trial of
the drug device combination product for Selatogrel with Idorsia
Pharmaceuticals and FDA and global regulatory approvals and future
revenue from the same; FDA approval of Teva’s pending ANDAs for
both generic Forteo® and
Exenatide and future revenue from the same; the timing and results
of the Company’s or its partners’ research projects or clinical
trials of product candidates in development including the
Company’s endocrinology and urology
assets in development as well as Pfizer’s
undisclosed development product; actions by the FDA or other
regulatory agencies with respect to the Company’s products or
product candidates of its partners; continued growth in product,
development, licensing and royalty revenue; the Company’s ability
to meet loan extension and interest only payment milestones and the
ability to repay the debt obligation to Hercules Capital; the
Company’s ability to obtain financial and other resources for its
research, development, clinical, and commercial activities and
other statements regarding matters that are not historical facts,
and involve predictions. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. In some cases you can identify forward-looking
statements by terminology such as ''may'', ''will'', ''should'',
''would'', ''expect'', ''intend'', ''plan'', ''anticipate'',
''believe'', ''estimate'', ''predict'', ''potential'', ''seem'',
''seek'', ''future'', ''continue'', or ''appear'' or the negative
of these terms or similar expressions, although not all
forward-looking statements contain these identifying words.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K, and in the
Company's other periodic reports and filings with the Securities
and Exchange Commission. The Company cautions investors not to
place undue reliance on the forward-looking statements contained in
this press release. All forward-looking statements are based on
information currently available to the Company on the date hereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this press release, except as required by
law.
Contact:
Tram BuiVice President, Corporate Communications
and Investor Relations609-359-3016tbui@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Apr 2024 to May 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From May 2023 to May 2024